Seetrue Technology, LLC

Seetrue Technology, LLC, doing business as Seetrue Technology LLC, is a woman-owned small business registered to receive federal government awards since November 2, 2017. The company specializes in developing innovative microinjection technologies for biomedical research and clinical applications. Seetrue Technology focuses on creating advanced 3D-printed microcapillary needles and microneedle arrays that address limitations of conventional microinjection tools. These technologies aim to enhance the delivery of gene therapies, cell-based treatments, and other substances into biological targets such as cells, embryos, and tissues.

Through federal grant awards, Seetrue Technology has engaged in multiple research and development projects to advance its microinjection technologies. The company received a $296,043 project grant from the National Institute of General Medical Sciences (NIGMS) to develop mechanically robust 3D-printed microcapillary needles with anti-clogging capabilities. This project aims to create durable microneedles that improve experimental reproducibility and efficacy in biomedical research. Additionally, Seetrue Technology was awarded an $807,694 project grant by the National Institute of Mental Health (NIMH) to develop 3D-printed microneedle array (MNA) technologies for enhanced delivery of gene therapies and cell-based treatments into the brain. This project focuses on overcoming limitations of current industry-standard microinjection needles to improve therapeutic coverage and reduce tissue damage in neurological applications. The company has also received support from the National Science Foundation (NSF) for a project involving three-dimensional printing of micro-capillary needles via direct laser writing. These federal grants demonstrate Seetrue Technology's commitment to advancing microinjection technologies for diverse biomedical applications, ranging from basic research to potential clinical treatments.